218 related articles for article (PubMed ID: 35937254)
1. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
Liu Y; Yi H; Fang K; Bao Y; Li X
Front Public Health; 2022; 10():942638. PubMed ID: 35937254
[TBL] [Abstract][Full Text] [Related]
2. Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study.
Fang W; Xu X; Zhu Y; Dai H; Shang L; Li X
Front Public Health; 2021; 9():714127. PubMed ID: 34422752
[No Abstract] [Full Text] [Related]
3. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
[TBL] [Abstract][Full Text] [Related]
4. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.
Cai L; Tao T; Li H; Zhang Z; Zhang L; Li X
J Glob Health; 2022 Dec; 12():11016. PubMed ID: 36527382
[TBL] [Abstract][Full Text] [Related]
5. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
Sun Y; Zhu Z; Zhang J; Han P; Qi Y; Wang X; Yang L
Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457445
[TBL] [Abstract][Full Text] [Related]
6. Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.
Zhu H; Zhu J; Zhou Y; Shan L; Li C; Cui Y; Kang Z; Jiao M; Liu H; Gao L; Wu Q; Hao Y
Front Public Health; 2022; 10():921093. PubMed ID: 35844892
[TBL] [Abstract][Full Text] [Related]
7. Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis.
Li C; Zhu J; Shan L; Zhou Y; Liu G; Zhu H; Wu Q; Cui Y; Kang Z
BMC Health Serv Res; 2024 Jan; 24(1):90. PubMed ID: 38233857
[TBL] [Abstract][Full Text] [Related]
8. Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.
Wang X; Huang H; Sun Y; Zhu Z; Jiang B; Yang L
BMJ Open; 2023 Jul; 13(7):e064199. PubMed ID: 37407064
[TBL] [Abstract][Full Text] [Related]
9. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
10. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis.
Zhang L; Wang X; Yao H; Ding B; Gao X; Li X
Int J Equity Health; 2024 Jun; 23(1):116. PubMed ID: 38840134
[TBL] [Abstract][Full Text] [Related]
11. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
12. The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis.
Wen X; Yin S; Cui L; Mao L; Lin Z; Yaermaimaiti Z; Geng X; Li Y; Yang Y; Cui D; Mao Z
Front Public Health; 2021; 9():718013. PubMed ID: 34760861
[No Abstract] [Full Text] [Related]
13. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
[TBL] [Abstract][Full Text] [Related]
14. How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study.
Diao Y; Qian J; Liu Y; Zhou Y; Wang Y; Ma H; Wang X; Luo R; Wagner A; Sun J; Liu Y
J Glob Health; 2019 Dec; 9(2):020702. PubMed ID: 31673344
[TBL] [Abstract][Full Text] [Related]
15. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
Lan T; Guan L; Pang X; Li X; Yu Q
J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
[TBL] [Abstract][Full Text] [Related]
16. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.
Yang Y; Zhang Y; Wagner AK; Li H; Shi L; Guan X
J Glob Health; 2023 Aug; 13():04083. PubMed ID: 37566690
[TBL] [Abstract][Full Text] [Related]
17. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
Zhao B; Wu J
Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
[TBL] [Abstract][Full Text] [Related]
18. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
Rong X; Yin J; Duan S; Sun Q; Babar ZU
BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
[TBL] [Abstract][Full Text] [Related]
19. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
[TBL] [Abstract][Full Text] [Related]
20. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
